Drugs, gene transfer, signaling factors: A bench to bedside approach to myocardial stem cell therapy

Marton Vertesaljai, Zsolt Piroth, Geza Fontos, Gyorgy Andreka, Gusztav Font, Gergely Szantho, Sandor Lueff, Marienn Reti, Tamas Masszi, Laszlo Ablonczy, Eszter D. Juhasz, Tamas Simor, Mark S. Turner, Peter Andreka

Research output: Contribution to journalArticle

10 Citations (Scopus)


In the past few years, the dogma that the heart is a terminally differentiated organ has been challenged. Evidence from preclinical investigations emerged that there are cells, even in the heart itself, that may be able to restore impaired cardiac function after myocardial infarction. Although the exact mechanisms by which the infarcted heart can be repaired by stem cells are not yet fully defined, there is a new optimism among cardiologists that this treatment will prove successful in addressing the cause of heart failure after myocardial infarction - myocyte loss. Despite the promising preliminary data of human myocardial stem cell trials, scientists have also focused on the possibility of enhancing the underlying mechanisms of stem cell repair to gain healthier myocardial tissue. Attempts to induce neo-angiogenesis by transfecting stem cells with signaling factors (such as VEGF), to raise the number of endothelial progenitor cells with medical treatments (such as statins), to transfect stem cells with heat shock protein 70 (as a cardioprotective agent against ischemia) and to enhance the healing process after myocardial infarction with the use of various forms of stimulating factors (G-CSF, SCF, GM-CSF) have been made with notable results. In this article, we summarize the evidence from preclinical and clinical myocardial stem cell studies that have addressed the possibility of enhancing the regenerative capacity of cells used after myocardial infarction.

Original languageEnglish
Pages (from-to)227-244
Number of pages18
JournalHeart Failure Reviews
Issue number2
Publication statusPublished - Jun 1 2008


  • Cardiac regeneration
  • Heart failure
  • Myocardial infarction
  • Signaling factors
  • Stem cells
  • Transplantation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Drugs, gene transfer, signaling factors: A bench to bedside approach to myocardial stem cell therapy'. Together they form a unique fingerprint.

  • Cite this

    Vertesaljai, M., Piroth, Z., Fontos, G., Andreka, G., Font, G., Szantho, G., Lueff, S., Reti, M., Masszi, T., Ablonczy, L., Juhasz, E. D., Simor, T., Turner, M. S., & Andreka, P. (2008). Drugs, gene transfer, signaling factors: A bench to bedside approach to myocardial stem cell therapy. Heart Failure Reviews, 13(2), 227-244. https://doi.org/10.1007/s10741-007-9047-9